Osilodrostat

Osilodrostat

Systematic (IUPAC) name
4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile
Clinical data
Routes of administration	Oral
Identifiers
CAS Number	928134-65-0
PubChem	CID: 44139752
ChemSpider	29340911
UNII	5YL4IQ1078
ChEMBL	CHEMBL3099695
Synonyms	LCI-699
Chemical data
Formula	C13H10FN3
Molecular mass	227.242 g/mol
SMILES C1CC2=CN=CN2[C@H]1C3=C(C=C(C=C3)C#N)F
InChI InChI=1S/C13H10FN3/c14-12-5-9(6-15)1-3-11(12)13-4-2-10-7-16-8-17(10)13/h1,3,5,7-8,13H,2,4H2/t13-/m1/s1 Key:USUZGMWDZDXMDG-CYBMUJFWSA-N

Osilodrostat (INN, USAN) (developmental code name LCI-699) is an orally active, non-steroidal corticosteroid biosynthesis inhibitor which is under development by Novartis for the treatment of Cushing's syndrome and pituitary ACTH hypersecretion (a specific subtype of Cushing's syndrome). It specifically acts as a potent and selective inhibitor of aldosterone synthase (CYP11B2) and at higher dosages of 11β-hydroxylase (CYP11B1). The drug was also under development for the treatment of heart failure, hypertension, and solid tumors, but development was discontinued for these indications. As of 2017, osilodrostat is in phase III and phase II clinical trials for treatment of pituitary ACTH hypersecretion and Cushing's syndrome, respectively.

See also

• Levoketoconazole

External links

• Osilodrostat - AdisInsight